In this webinar, Dr. Jeff S. Xue and Dr. Brandon Lamarche discuss research solutions from ACEA Biosciences, a new part of Agilent Technologies. With the addition of the xCELLigence Real Time Cell Analyzers (RTCA) and NovoCyte flow cytometers, Agilent provides best-in-class tools for quantitative assessment of cell health, behavior, function, phenotype, fitness, and fate. The newly launched xCELLigence RTCA eSight platform uses impedance biosensors to continuously monitor changes in cell number, cell morphology, cell-substrate attachment strength, and cell barrier function while simultaneously tracking the same population of cells via three-color live cell imaging. The benefits of this multiplexed live cell analysis, which involves a simple workflow, are demonstrated within the context of diverse applications.
In this webinar, we will discuss:
- How Agilent’s new product lines support the discovery, development, and manufacturing of next-generation therapies.
- How the new xCELLigence RTCA eSight platform combines the strengths of real-time biosensor-based impedance monitoring (simplicity, analytical sensitivity, and objectivity) with that of live cell imaging (readout specificity).
- How eSight is being used for diverse applications, including assessing: (1) the activity/potency of immune cells, antibodies, and targeted therapies for killing cancer cells, (2) cell migration, and (3) cell stress (apoptosis, unfolded protein response).